Dyne Therapeutics (DYN) Stock Forecast & Price Target

Compare

451 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DYN Analyst Ratings

Strong Buy

6 Buy

1 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Dyne

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DYN Stock 12 Month Forecast

Average Price Target

$39.57

▲(125.35% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Dyne Therapeutics in the last 3 months. The average price target is $39.57 with a high forecast of $50.00 and a low forecast of $16.00. The average price target represents a 125.35% change from the last price of $17.56.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","18":"$18","29":"$29","40":"$40","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.57142857142857,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,18,29,40,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.15,18.75384615384615,21.357692307692307,23.96153846153846,26.565384615384616,29.16923076923077,31.77307692307692,34.37692307692308,36.980769230769226,39.58461538461538,42.18846153846154,44.79230769230769,47.396153846153844,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.15,17.951648351648352,19.7532967032967,21.554945054945055,23.356593406593404,25.158241758241758,26.95989010989011,28.76153846153846,30.56318681318681,32.36483516483516,34.16648351648352,35.96813186813186,37.769780219780216,{"y":39.57142857142857,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.15,16.138461538461538,16.126923076923077,16.115384615384613,16.103846153846153,16.092307692307692,16.08076923076923,16.069230769230767,16.057692307692307,16.046153846153846,16.034615384615385,16.02307692307692,16.01153846153846,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.58,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.61,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.56,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$39.57

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tessa Romero

J.P. Morgan

$16

Hold

-8.88%

Downside

Reiterated

03/16/26

J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN)

Ananda Ghosh

H.C. Wainwright

$50

Buy

184.74%

Upside

Reiterated

03/09/26

Buy Rating on Dyne Therapeutics Driven by Robust Phase 3 DM1 Endpoint Strategy and Emerging Disease‑Modification Data

Michael Ulz

Morgan Stanley

$14.86→$47

Buy

167.65%

Upside

Reiterated

03/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Biohaven Ltd. (NYSE: BHVN) and Teladoc (NYSE: TDOC)

Francois Brisebois

LifeSci Capital

$44

Buy

150.57%

Upside

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (NASDAQ: JBIO) and Dyne Therapeutics (NASDAQ: DYN)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$50

Buy

184.74%

Upside

Initiated

03/08/26

Dyne Therapeutics (DYN) Receives a Buy from Guggenheim

Andreas Argyrides

Oppenheimer

$40

Buy

127.79%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Prime Medicine, Inc. (NASDAQ: PRME) and Pharvaris (NASDAQ: PHVS)

Luca Issi

RBC Capital

$30

Buy

70.84%

Upside

Reiterated

03/02/26

Dyne Therapeutics (DYN) Gets a Buy from RBC Capital

Gavin Clark-Gartner

Evercore ISI

$36

Buy

105.01%

Upside

Reiterated

12/17/25

Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISIDyne Therapeutics price target lowered to $36 from $38 at Evercore ISI

Paul Matteis

Stifel Nicolaus

$36

Buy

105.01%

Upside

Reiterated

12/15/25

Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus

William Pickering

Bernstein

$21→$23

Hold

30.98%

Upside

Reiterated

12/09/25

Dyne Therapeutics price target raised to $23 from $21 at BernsteinDyne Therapeutics price target raised to $23 from $21 at Bernstein

Edward Tenthoff

Piper Sandler

$48

Buy

173.35%

Upside

Reiterated

12/01/25

Dyne Therapeutics (DYN) Gets a Buy from Piper Sandler

Martin Auster

Raymond James

$31→$35

Buy

99.32%

Upside

Reiterated

08/25/25

Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesDyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James

Louise Chen

Scotiabank

$50

Buy

184.74%

Upside

Reiterated

07/29/25

Dyne Therapeutics (DYN) Gets a Buy from Scotiabank

Keay Nakae

Chardan Capital

$50→$38

Buy

116.40%

Upside

Reiterated

07/28/25

Chardan Capital Sticks to Its Buy Rating for Dyne Therapeutics (DYN)

Catherine Novack

JonesTrading

$30

Buy

70.84%

Upside

Initiated

06/25/25

Dyne Therapeutics initiated with a Buy at JonesResearchDyne Therapeutics initiated with a Buy at JonesResearch

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tessa Romero

J.P. Morgan

$16

Hold

-8.88%

Downside

Reiterated

03/16/26

J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN)

Ananda Ghosh

H.C. Wainwright

$50

Buy

184.74%

Upside

Reiterated

03/09/26

Buy Rating on Dyne Therapeutics Driven by Robust Phase 3 DM1 Endpoint Strategy and Emerging Disease‑Modification Data

Michael Ulz

Morgan Stanley

$14.86→$47

Buy

167.65%

Upside

Reiterated

03/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Biohaven Ltd. (NYSE: BHVN) and Teladoc (NYSE: TDOC)

Francois Brisebois

LifeSci Capital

$44

Buy

150.57%

Upside

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (NASDAQ: JBIO) and Dyne Therapeutics (NASDAQ: DYN)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$50

Buy

184.74%

Upside

Initiated

03/08/26

Dyne Therapeutics (DYN) Receives a Buy from Guggenheim

Andreas Argyrides

Oppenheimer

$40

Buy

127.79%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), Prime Medicine, Inc. (NASDAQ: PRME) and Pharvaris (NASDAQ: PHVS)

Luca Issi

RBC Capital

$30

Buy

70.84%

Upside

Reiterated

03/02/26

Dyne Therapeutics (DYN) Gets a Buy from RBC Capital

Gavin Clark-Gartner

Evercore ISI

$36

Buy

105.01%

Upside

Reiterated

12/17/25

Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISIDyne Therapeutics price target lowered to $36 from $38 at Evercore ISI

Paul Matteis

Stifel Nicolaus

$36

Buy

105.01%

Upside

Reiterated

12/15/25

Dyne Therapeutics (DYN) Gets a Buy from Stifel Nicolaus

William Pickering

Bernstein

$21→$23

Hold

30.98%

Upside

Reiterated

12/09/25

Dyne Therapeutics price target raised to $23 from $21 at BernsteinDyne Therapeutics price target raised to $23 from $21 at Bernstein

Edward Tenthoff

Piper Sandler

$48

Buy

173.35%

Upside

Reiterated

12/01/25

Dyne Therapeutics (DYN) Gets a Buy from Piper Sandler

Martin Auster

Raymond James

$31→$35

Buy

99.32%

Upside

Reiterated

08/25/25

Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond JamesDyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James

Louise Chen

Scotiabank

$50

Buy

184.74%

Upside

Reiterated

07/29/25

Dyne Therapeutics (DYN) Gets a Buy from Scotiabank

Keay Nakae

Chardan Capital

$50→$38

Buy

116.40%

Upside

Reiterated

07/28/25

Chardan Capital Sticks to Its Buy Rating for Dyne Therapeutics (DYN)

Catherine Novack

JonesTrading

$30

Buy

70.84%

Upside

Initiated

06/25/25

Dyne Therapeutics initiated with a Buy at JonesResearchDyne Therapeutics initiated with a Buy at JonesResearch

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dyne Therapeutics

3 Months

xxx

Success Rate

14/24 ratings generated profit

Average Return

+8.96%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +8.96% per trade.

1 Year

Keay NakaeChardan Capital

Success Rate

10/15 ratings generated profit

Average Return

+50.09%

Copying Keay Nakae's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +50.09% per trade.

2 Years

xxx

Success Rate

8/15 ratings generated profit

Average Return

+62.55%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 53.33% of your transactions generating a profit, with an average return of +62.55% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DYN Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DYN has received 10 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. DYN average Analyst price target in the past 3 months is 39.57.

Each month's total comprises the sum of three months' worth of ratings.

DYN Financial Forecast

DYN Earnings Forecast

Next quarter’s earnings estimate for DYN is -$0.77 with a range of -$1.08 to -$0.64. The previous quarter’s EPS was -$0.76. DYN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year DYN has Performed in-line its overall industry.

No data currently available

DYN Sales Forecast

Next quarter’s sales forecast for DYN is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DYN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year DYN has Performed in-line its overall industry.

DYN Stock Forecast FAQ

What is DYN’s average 12-month price target, according to analysts?

Based on analyst ratings, Dyne Therapeutics’s 12-month average price target is 39.57.

What is DYN’s upside potential, based on the analysts’ average price target?

Dyne Therapeutics has 125.35% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DYN a Buy, Sell or Hold?

Dyne Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.

What is Dyne Therapeutics’s price target?

The average price target for Dyne Therapeutics is 39.57. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $16.00. The average price target represents 125.35% Increase from the current price of $17.56.

What do analysts say about Dyne Therapeutics?

Dyne Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of DYN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Dyne Therapeutics (DYN) Stock Forecast & Price Target

DYN Analyst Ratings

DYN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dyne Therapeutics

DYN Analyst Recommendation Trends

DYN Financial Forecast

DYN Earnings Forecast

DYN Sales Forecast

DYN Stock Forecast FAQ

Detailed List of Analyst Forecasts